fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Understanding the systemic inflammatory response in covid-19

Written by | 2 Mar 2021

Interview and article by Christine Clark Although SARS-CoV-2 causes a mild illness in many people, some experience severe illness characterised by a systemic inflammatory response that can lead… read more.

Pfizer and BioNTech SE initiate a study as part of broad development plan to evaluate COVID 19 booster and new vaccine variants

Written by | 1 Mar 2021

Pfizer Inc.and BioNTech SE announced they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the… read more.

Vaccination potential will not be achieved without increased production, affordable pricing, global availability, and successful rollout

Written by | 26 Feb 2021

To ensure an effective global immunisation strategy against COVID-19, vaccines need to be produced at scale, priced affordably, and allocated globally so that they are available where needed,… read more.

Health Canada approves Assure Tech Ecotest COVID-19 serological rapid test for COVID-19 – Verify Diagnostics

Written by | 26 Feb 2021

Verify Diagnostics announced that Health Canada has authorized the Assure Tech Ecotest COVID-19 serological rapid test to be used at the point-of-care (POC) for the purpose of screening… read more.

Pfizer and BioNTech submit COVID-19 vaccine stability data at standard freezer temperature to the FDA

Written by | 23 Feb 2021

Pfizer Inc. and BioNTech SE announced the submission of new data to the FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F… read more.

Putting the SHAPES pilot project into action

Written by | 23 Feb 2021

Interview and article by Christine Clark Dr Maureen Spargo and Dr Nicola Goodfellow describe how SHAPES, a pan-European digital healthcare project is being put into action in Northern… read more.

WHO gives COVID-19 Vaccine AstraZeneca Emergency Use Listing for COVID-19 – AstraZeneca

Written by | 21 Feb 2021

AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age… read more.

Anticoagulation appears to lower Covid-19 mortality

Written by | 20 Feb 2021

Article written by Bruve Sylvester Covid-19 patients treated with preventive blood thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital have lower subsequent mortality than covid-19… read more.

Ivabradine shows efficacy in treating postural orthostatic tachycardia syndrome (POTS)

Written by | 19 Feb 2021

Article written by Bruce Sylvester Researchers report that ivabradine, a drug used for heart failure, appears to improve symptoms of postural orthostatic tachycardia syndrome, also known as POTS.

Phase III data update for CoronaVac in COVID-19 – Sinovac Biotech

Written by | 18 Feb 2021

Sinovac Biotech has announced phase III results of CoronaVac in COVID-19 treatment.

Gout drug shows preliminary efficacy with hospitalized COVID-19 patients

Written by | 18 Feb 2021

Article written by Bruce Sylvester Colchicine, a gout treatment, appears to reduce the need for oxygen therapy in COVID-19 patients, researchers reported on Feb. 4, 2021 in the… read more.

Ivermectin mass treatment in perspective

Written by | 17 Feb 2021

Interview and article by Christine Clark. Ivermectin is a good treatment to use interim to and complementary to immunisations, according to Dr David Scheim, one of the authors… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.